Laboratorijas rokasgrāmata · Augšanas hormona ass
What Is CJC-1295 With DAC? Albumin-Binding GHRH Analogue Research Overview
What is CJC-1295 With DAC? It is a growth hormone-releasing hormone analogue carrying a drug affinity complex, a maleimide group that bonds covalently to serum albumin and extends its time in circulation to days. This guide explains that chemistry, the published pharmacokinetic findings, and how the compound differs from the no-DAC form.
Galvenie secinājumi
- CJC-1295 is a tetrasubstituted hGRF(1-29) with an N-epsilon-3-maleimidopropionamide lysine at the C terminus, which reacts with albumin to form a covalent conjugate.
- In rats, it produced a four-fold greater GH area under the curve over two hours than hGRF(1-29) and persisted in plasma beyond 72 hours (Jetté et al., 2005).
- In healthy adults, a single dose raised mean GH 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9-11 days (Teichman et al., 2006).
- Pulsatile GH secretion was preserved while trough levels rose, an experimental variable that separates it from the short-acting no-DAC peptide.
What is CJC-1295 With DAC?
So, what is CJC-1295 With DAC? CJC-1295 is the long-acting GHRH analogue described by Jetté et al. (2005, Endocrinology): a tetrasubstituted form of hGRF(1-29) with an N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus. That group is the drug affinity complex (DAC). Researchers also write it DAC:GRF. The shorter-acting peptide without this group is covered in What is CJC-1295 No DAC.
Tikai pētniecības vajadzībām. Šajā pārskatā apkopoti publicētie laboratorijas un dzīvnieku pētījumu rezultāti. Uzņēmums „ Baltic Peptides “ piegādā šo savienojumu kvalificētiem pētniekiem in vitro un pirmsklīniskajiem pētījumiem; tas nav zāles un nav paredzēts lietošanai cilvēkiem vai dzīvniekiem.
Ķīmiskā struktūra un tehniskie parametri
| Īpašums | Value (as listed on the Baltic Peptides product page) |
|---|---|
| Core peptide | [D-Ala2, Gln8, Ala15, Leu27]-GHRH(1-29) |
| DAC | Lys30 carrying an epsilon-maleimidopropionyl group |
| Molekulārā formula | C165H269N47O46 |
| Molekulmasa | 3647,2 g/mol |
| CAS numurs | 446262-90-4 |
The formula is consistent with the no-DAC peptide plus one lysine residue plus the maleimidopropionyl group, which I checked by adding the atoms. I could not confirm the mass or CAS number in PubChem, so they are given as supplier values; confirm identity from the batch mass. The maleimide hydrolyses in water to a ring-opened form that adds 18 Da and can no longer bind albumin, so mass spectrometry also reports on maleimide integrity.
Atklāšanas un pētniecības vēsture
CJC-1295 was developed using a drug affinity complex platform. Jetté et al. (2005, Endocrinology) showed in rats that the conjugate was found bound to albumin, was present in plasma beyond 72 hours, and produced a four-fold larger GH response than hGRF(1-29).
Teichman et al. (2006) then studied it in healthy adults, and a once-daily dosing study and Ionescu and Frohman (2006) followed.
Mechanism: albumin conjugation and GHRH receptor activation
Covalent albumin binding
The maleimide reacts with the free thiol of cysteine-34 on circulating albumin to form a stable thioether bond. The albumin-bound peptide remains an agonist at the GHRH receptor but is protected from rapid clearance and degradation.
Receptor signalling
As with native GHRH, receptor activation on pituitary somatotrophs raises cAMP and stimulates GH release. The altered feature is exposure time, not receptor selectivity.
Galvenās pētījumu jomas
- Pharmacokinetics: albumin conjugation as a model of half-life extension.
- Chronic receptor stimulation: adaptation and desensitisation under sustained agonism.
- GH and IGF-I dynamics: trough and mean levels versus pulsatility.
- Bioconjugation chemistry: maleimide-thiol reactions in peptide design.
Ko faktiski liecina publicētie pētījumi
| Pierādījumu veids | Kas tiek ziņots |
|---|---|
| Rats | Four-fold greater GH AUC than hGRF(1-29) over 2 hours; plasma presence beyond 72 hours (Jetté et al. (2005, Endocrinology)). |
| Healthy adults | Single dose: GH up 2- to 10-fold for six days or more and IGF-I up 1.5- to 3-fold for 9-11 days; IGF-I stayed above baseline for up to 28 days after repeated dosing (Teichman et al. (2006)). |
| Pulsatility | Pulse frequency and magnitude were unaltered, while basal GH rose 7.5-fold and mean GH 46% (Ionescu and Frohman (2006)). |
| Pusperiods | The Ionescu and Frohman abstract gives 8 days; Baltic Peptides cites 5.8-8.1 days for Teichman et al. |
These are controlled studies in small numbers of healthy volunteers. The authors of the 2006 study described the compound as safe and relatively well tolerated at the doses tested, which does not establish long-term safety.
Zinātniskie ierobežojumi un neatrisinātie jautājumi
- Human studies were small, short and performed more than 15 years ago.
- Sustained receptor stimulation changes the GH profile, so findings do not apply to pulsatile analogues.
- The compound has no EMA or FDA approval, and early clinical studies do not change its research-only status.
- Supplier masses and CAS numbers could not be cross-checked against PubChem.
- GHRH analogues are prohibited in sport under the WADA Prohibited List.
Analītiskie un laboratorijas apsvērumi
Mass spectrometry should show the intact conjugate at about 3647 Da and should distinguish it from the hydrolysed, ring-opened form (+18 Da) that cannot bind albumin. HPLC should resolve truncated sequences. Because the maleimide hydrolyses in water, faster at higher pH and temperature, handling should limit time in aqueous solution; this is a stability consideration for experiments rather than a procedure.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the CJC-1295 With DAC product page.
Avoti un papildu literatūra
- Jetté L. et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PubMed
- Teichman S.L. et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 91(3):799-805. PubMed
- Ionescu M. and Frohman L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. PubMed
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog (2006). PubMed
Visi „ Baltic Peptides “ produkti tiek piegādāti tikai laboratorijas pētniecības vajadzībām. Tie nav zāles, uztura bagātinātāji vai pārtikas produkti, un tie nav paredzēti lietošanai cilvēkiem vai dzīvniekiem. Šajā rakstā izklāstīti publicēto pētījumu kopsavilkumi, kas paredzēti vienīgi izglītojošiem nolūkiem, un tajā nav aprakstīta to lietošana cilvēkiem.
Bieži uzdotie jautājumi
Bieži uzdotie jautājumi
What is CJC-1295 With DAC?
What does the drug affinity complex do?
What is the half-life of CJC-1295 With DAC?
What did the 2006 human study find?
Does CJC-1295 With DAC change GH pulsatility?
How is CJC-1295 With DAC different from CJC-1295 No DAC?
Is CJC-1295 With DAC an approved medicine?
Lasiet tālāk
Ieteicamā literatūra
CJC-1295 ar DAC
Current batches, formats and the COA for CJC-1295 With DAC.
Kas ir CJC-1295 bez DAC?
The short-acting peptide without the albumin-binding group.
Paskaidrojums par peptīdu maisījumiem
Kāpēc komponentu pētījumi nenosaka kombinēto sastāvu?
Research-grade CJC-1295 With DAC, tested before it ships
Neatkarīgie „ HPLC ” un masu spektrometrijas rezultāti katrai partijai, kas tiek nosūtīta no ES.
